Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.


Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety of other diseases, including diabetes, pain, cognition, and chronic inflammatory and immunologic diseases. However, as the vast majority of current… (More)
DOI: 10.1021/cb1002619


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.